In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remaine ...

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ...

Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease control rate and durable disease stabilization; one of two confirmed responders remains on study ~40 weeks after ...

The placebo-controlled, randomised, double-blind study plans to enrol around 2,136 patients across 28 countries.

Rivia Expands Clinical Trial Intelligence Platform with New AI-Powered Data Findings Module New module enables continuous, automated review of clinical trial data, helping drug developers identify ...

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company developing potentially ...

Ractigen Therapeutics, a leading clinical-stage biopharmaceutical company developing innovative small activating RNA (saRNA) ...

Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadin Protocol ...

WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...

Drug development is a stepwise process, with each clinical phase answering a different question about a treatment's safety ...

WHO backs Moderna and Oxford Ebola vaccine candidates for testing in DRC’s Tumaini trial, the first efficacy study targeting ...